Evidence map›Paper›PMID 29693332›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2018

Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis

Ricvan Dana Nindrea, Wirsma Arif Harahap, Teguh Aryandono, Lutfan Lazuardi

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Higher Levels ofMedical sciences (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Genes · 2026
    Article
  6. The Transcriptomic Profile Underlying Somatic MonoallelicDiagnostics (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ricvan Dana NindreaDoctoral Program, Faculty of Medicine, Universitas Gadjah Mada, Indonesia. Email: ricvandana7@gmail.com
Wirsma Arif Harahap
Teguh Aryandono
Lutfan Lazuardi
Universitas Gadjah Mada · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study was to determine the degree of association of BRCA1 promoter methylation with breast cancer in Asia. Methods: The study sample for the present meta-analysis was provided by published research articles on associations of BRCA1 promoter methylation with breast cancer in Asia accessed through databases on PubMed, ProQuest and EBSCO published between 1997 and November 2017. Pooled odds ratios (OR) were calculated with fixed and random-effect models. Data were processed using Review Manager 5.3 (RevMan 5.3). Results: Of a total of 475 articles, 11 studies were included in our systematic review with meta-analysis of relevant data. The results showed a highly significant association between BRCA1 promoter methylation with breast cancer in Asia (OR = 8.78 [95% CI 4.15-18.56, p < 0.00001]). Conclusion: This analysis confirmed association between BRCA1 promoter methylation and breast cancer in Asia. BRCA1 promoter assessment might be a predictive or diagnostic aid for breast cancer prediction.

Indexed as

DNA MethylationGenetic Predisposition to DiseasePromoter Regions, GeneticBRCA1 ProteinBreast NeoplasmsFemaleHumansPrognosisBRCA1 ProteinBRCA1 protein, humanAsiaBRCA1breast cancermethylation

Identifiers

PMID29693332
PMCPMC6031799
OpenAlexW2787969363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.